ABSTRACT OF THE DISCLOSURE

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure:

$$\begin{array}{c} O \\ R_4 \\ R_3 \end{array} \begin{array}{c} R_5 \\ N \\ N \\ N \end{array} \begin{array}{c} X \\ N \\ R_2 \end{array} \begin{array}{c} R_1 \\ N \\ R_2 \end{array}$$

including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R_1 , R_2 , R_3 , R_4 , and R_5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

690068.575\459935_2.DOC